MA
$118.61
+1.84
(+1.58%)
As of Oct 5, 2026, 3:36 PM EDT
Price history
Veradermics (MANE) is trading up at $118.61 (+1.58%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: February 4, 2026 · $17.00 offering · NYSE · View IPO details →
Veradermics net income history (FY2024–FY2025)
Net income
| FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|
| Income statement | ||
| Operating income | −$26.8M | −$72.3M |
| Net income | −$26.5M | −$70.0M |
| EPS (diluted) | −$37.05 | −$111.91 |
| Balance sheet | ||
| Cash and equivalents | $53.1M | $21.8M |
| Total assets | $55.5M | $152.6M |
| Total liabilities | $4.72M | $9.16M |
| Shareholders' equity | −$48.5M | −$121.0M |
| Cash flow | ||
| Operating cash flow | −$23.7M | −$71.6M |
| Capital expenditure | $0 | $24.0K |
| Free cash flow | −$23.7M | −$71.6M |
Net income
| Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Operating income | −$12.9M | −$16.1M | — | −$29.9M | −$29.6M |
| Net income | −$12.4M | −$15.6M | — | −$27.2M | −$23.5M |
| EPS (diluted) | −$19.79 | −$24.19 | — | −$1.32 | −$0.58 |
| Balance sheet | |||||
| Cash and equivalents | $32.4M | $8.60M | $21.8M | $168.4M | $319.3M |
| Total assets | — | — | $152.6M | $397.4M | $825.7M |
| Total liabilities | — | — | $9.16M | $6.72M | $12.1M |
| Shareholders' equity | −$60.7M | −$76.1M | −$121.0M | $390.6M | $813.6M |
| Cash flow | |||||
| Operating cash flow | −$13.3M | −$15.6M | — | −$21.2M | −$14.5M |
| Capital expenditure | $19.0K | $0 | — | $0 | $21.0K |
| Free cash flow | −$13.3M | −$15.6M | — | −$21.2M | −$14.5M |
From Veradermics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
About Veradermics
- Headquarters
- New Haven, Connecticut From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International